UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000025767
Receipt number R000029642
Scientific Title The study for association between circulating angiopoetin like protein 2 (ANGPTL2) and various markers related to diabetes in patients with type 2 diabetes
Date of disclosure of the study information 2017/01/22
Last modified on 2022/01/24 18:41:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study for association between circulating angiopoetin like protein 2 (ANGPTL2) and various markers related to diabetes in patients with type 2 diabetes

Acronym

Association between circulating ANGPTL2 and various markers related to DM in T2DM patients

Scientific Title

The study for association between circulating angiopoetin like protein 2 (ANGPTL2) and various markers related to diabetes in patients with type 2 diabetes

Scientific Title:Acronym

Association between circulating ANGPTL2 and various markers related to DM in T2DM patients

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Medicine in general Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the association between ANGPTL2 and various markers related to type 2 diabetes or atherosclerosis or between ANGPTL2 and degrees of progression of diabetic complications by cross-sectional analysis

Basic objectives2

Others

Basic objectives -Others

The association between ANGPTL2 and other bloods markers excluding Narrative objectives1

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Association between ANGPTL2 and various markers related to type 2 diabetes or atherosclerosis or between ANGPTL2 and degrees of progression of diabetic complications (cross-sectional)

Key secondary outcomes

None


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) patients (male or femal) aged 20 or over at enrollment
2) patients diagnosed as type 2 diabetes (based on criteria in Japan Diabetes Society 2010)
3)Patients who are hospitalized for glycemic control for type 2 diabetes
4)patients giving consent in writing for participation for this study

Key exclusion criteria

1)Patients with type 1 diabetes, pancreatic diabetes or secondary diabetes (Cushing syndrome, acromegaly etc.) diabetic coma or diabetic pre-coma, or type 1 diabetes
2)Patients under pregnancy, possible pregnancy, or lactation
3)Furthermore, patients judged as inadequacy for participation in this study by medical doctor

Target sample size

70


Research contact person

Name of lead principal investigator

1st name Kohzo
Middle name
Last name Takebayashi

Organization

Dokkyo Medical University Koshigaya Hospital

Division name

Internal Medicine (Diabetes, Endocrinology, Hematology)

Zip code

343-85555

Address

2-1-50 Minamikoshigaya, Koshigaya, Saitama, Japan

TEL

048-965-1111

Email

takebaya@dokkyomed.ac.jp


Public contact

Name of contact person

1st name Kohzo T
Middle name
Last name Takebayashi

Organization

Dokkyo Medical University Koshigaya Hospital

Division name

Internal Medicine (Diabetes, Endocrinology, Hematology)

Zip code

343-8555

Address

2-1-50 Minamikoshigaya, Koshigaya, Saitama, Japan

TEL

048-965-1111

Homepage URL


Email

takebaya@dokkyomed.ac.jp


Sponsor or person

Institute

Dokkyo Medical University Koshigaya Hospital

Institute

Department

Personal name



Funding Source

Organization

None (Self funding)

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Dokkyo Medical University Koshigaya Hospital

Address

2-1-50 Minamikoshigaya, Koshigaya, Saitama, Japan

Tel

0489651111

Email

takebaya@dokkyomed.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 01 Month 22 Day


Related information

URL releasing protocol

https://journals.sagepub.com/doi/10.1177/0300060518791067

Publication of results

Unpublished


Result

URL related to results and publications

https://journals.sagepub.com/doi/10.1177/0300060518791067

Number of participants that the trial has enrolled

70

Results

The serum levels of ANGPTL2 were significantly elevated in the type 2 diabetic patients compared with that in the healthy controls. There was a significant positive correlation between ANGPTL2 and either high sensitivity C reactive protein, fibrinogen, or LAB levels, and a significant negative correlation between ANGPTL2 and estimated glomerular filtration rate (eGFR) levels.

Results date posted

2022 Year 01 Month 24 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Age 60(48.3, 72.8)year
Mean duration of diabetes 7(2, 11.8)year
BMI (kg/m2) 24.5 plus/minus 4.5
FPG (mg/dL)174(143.3, 257.8) mg/dl
HbA1c (%) 9.8(8.8, 11.7)
eGFR (ml/min/1.73 m2) 79.7 (64.2, 96.1)

Participant flow

A total of 70 hospitalized type 2 diabetic patients were prospectively and consecutively enrolled from February 2017 and to August 2017.

Adverse events

Not applicable

Outcome measures

Circulating ANGPTL2
PG , HbA1c
Diabetic complications

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2017 Year 01 Month 18 Day

Date of IRB

2017 Year 01 Month 20 Day

Anticipated trial start date

2017 Year 01 Month 22 Day

Last follow-up date

2017 Year 12 Month 02 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Cross-sectional study


Management information

Registered date

2017 Year 01 Month 20 Day

Last modified on

2022 Year 01 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029642


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name